[PDF][PDF] Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer
…, T Price, E Van Cutsem, M Hill, F Gilberg… - J Clin …, 2011 - researchgate.net
… Haller, Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem,
Mark Hill, Frank Gilberg, Karen Rittweger, and Hans-Joachim Schmoll … Haller, Filippo de …
Mark Hill, Frank Gilberg, Karen Rittweger, and Hans-Joachim Schmoll … Haller, Filippo de …
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
…, KU Kirchgaessler, K Samara, F Gilberg… - The lancet Respiratory …, 2020 - thelancet.com
Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
[HTML][HTML] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
…, R Wong, S Koski, K Rittweger, F Gilberg… - British journal of …, 2011 - nature.com
Background: We report updated overall survival (OS) data from study NO16966, which
compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (…
compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (…
[HTML][HTML] Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and …
…, G Van Hazel, A Wong, E Díaz-Rubio, F Gilberg… - Annals of oncology, 2012 - Elsevier
Background This multicenter randomized trial compared oral capecitabine with bolus iv 5-fluorouracil
(5-FU)/folinic acid (FA) as adjuvant therapy for stage III colon cancer. Patients and …
(5-FU)/folinic acid (FA) as adjuvant therapy for stage III colon cancer. Patients and …
[HTML][HTML] Potential regional differences for the tolerability profiles of fluoropyrimidines
…, F Gilberg, F Sirzén… - Journal of …, 2008 - scholarship.libraries.rutgers.edu
PurposeWe conducted a retrospective analysis of safety data from randomized, single-agent
fluoropyrimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to …
fluoropyrimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and capecitabine) to …
[HTML][HTML] A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
…, J Axmann, P Belloni, M Bengus, F Gilberg… - Respiratory …, 2022 - Springer
… spirometry and site spirometry in a STARLINER, all subjects, b STARLINER, IPF, c
STARLINER, non-IPF ILD, d STARMAP, e the pirfenidone in uILD study (placebo group) and f the …
STARLINER, non-IPF ILD, d STARMAP, e the pirfenidone in uILD study (placebo group) and f the …
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
… F Hoffmann-La Roche was the funder of the study. We thank all the patients and their
families, the … Financial support for editorial assistance was provided by F Hoffmann-La Roche. …
families, the … Financial support for editorial assistance was provided by F Hoffmann-La Roche. …
Fluoropyrimidine (FP)+ bevacizumab (BEV)+ atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL–a …
…, I Bosanac, S Srock, C Mancao, F Gilberg… - Annals of …, 2018 - annalsofoncology.org
Background: In patients (pts) with mCRC, molecular screening approaches and new
biomarkers are required to fully characterize tumours and identify those likely to benefit. The …
biomarkers are required to fully characterize tumours and identify those likely to benefit. The …
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind …
…, KU Kirchgaessler, M Bengus, F Gilberg… - The Lancet …, 2021 - thelancet.com
Background The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis
(IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or …
(IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or …
[HTML][HTML] Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
Background To compare the effects of oral capecitabine-containing chemotherapy regimens
with iv 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in …
with iv 5-fluorouracil (5-FU)-containing chemotherapy regimens on overall survival in …